

Geraldine Rauch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3569125/publications.pdf>

Version: 2024-02-01

80
papers

1,403
citations

394421

19
h-index

395702

33
g-index

89
all docs

89
docs citations

89
times ranked

1963
citing authors

#	ARTICLE	IF	CITATIONS
1	The Potential of Shear Wave Elastography to Reduce Unnecessary Biopsies in Breast Cancer Diagnosis: An International, Diagnostic, Multicenter Trial. <i>Ultraschall in Der Medizin</i> , 2023, 44, 162-168.	1.5	11
2	Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment for Reliable Exclusion of Residual Cancer in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2022, 29, 1076-1084.	1.5	15
3	Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy. <i>Annals of Surgery</i> , 2022, 275, 576-581.	4.2	38
4	ASO Visual Abstract: Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment to Reliably Exclude Residual Cancer in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2022, 29, 1085-1086.	1.5	0
5	The potential of combined shear wave and strain elastography to reduce unnecessary biopsies in breast cancer diagnostics – An international, multicentre trial. <i>European Journal of Cancer</i> , 2022, 161, 1-9.	2.8	21
6	Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria. <i>European Journal of Haematology</i> , 2022, 108, 391-402.	2.2	4
7	Review of guidance papers on regression modeling in statistical series of medical journals. <i>PLoS ONE</i> , 2022, 17, e0262918.	2.5	10
8	Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery. <i>Journal of Clinical Oncology</i> , 2022, 40, 1903-1915.	1.6	31
9	Weighted composite time to event endpoints with recurrent events: comparison of three analytical approaches. <i>BMC Medical Research Methodology</i> , 2022, 22, 38.	3.1	5
10	Abstract PD7-02: Intelligent vacuum-assisted breast biopsy to identify breast cancer patients with pathologic complete response after neoadjuvant systemic treatment for omission of breast and axillary surgery. <i>Cancer Research</i> , 2022, 82, PD7-02-PD7-02.	0.9	0
11	Abstract PD11-05: Intelligent shear-wave elastography to reduce unnecessary biopsies in breast cancer diagnosis (INSPIRED 002): An international, multicenter analysis. <i>Cancer Research</i> , 2022, 82, PD11-05-PD11-05.	0.9	0
12	The importance of multi-modal imaging and clinical information for humans and AI-based algorithms to classify breast masses (INSPIRED 003): an international, multicenter analysis. <i>European Radiology</i> , 2022, 32, 4101-4115.	4.5	8
13	FIRE-9 – PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer. <i>BMC Cancer</i> , 2022, 22, 359.	2.6	1
14	Discordance between estimated and measured changes in plasma volume among patients with acute heart failure. <i>ESC Heart Failure</i> , 2022, 9, 66-76.	3.1	7
15	On the feasibility of pediatric dose-finding trials in small samples with information from a preceding trial in adults. <i>Journal of Biopharmaceutical Statistics</i> , 2022, 32, 652-670.	0.8	0
16	Optimization of adaptive designs with respect to a performance score. <i>Biometrical Journal</i> , 2022, 64, 989-1006.	1.0	1
17	Selection of variables for multivariable models: Opportunities and limitations in quantifying model stability by resampling. <i>Statistics in Medicine</i> , 2021, 40, 369-381.	1.6	8
18	Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. <i>European Journal of Cancer</i> , 2021, 143, 134-146.	2.8	44

#	ARTICLE	IF	CITATIONS
19	The adoptr Package: Adaptive Optimal Designs for Clinical Trials in <i>R</i>. Journal of Statistical Software, 2021, 98, .	3.7	5
20	Impact of the COVID-19 shutdown on orthopedic trauma numbers and patterns in an academic Level I Trauma Center in Berlin, Germany. PLoS ONE, 2021, 16, e0246956.	2.5	23
21	Optimal planning of adaptive two-stage designs. Statistics in Medicine, 2021, 40, 3196-3213.	1.6	6
22	Smoothing Corrections for Improving Sample Size Recalculation Rules in Adaptive Group Sequential Study Designs. Methods of Information in Medicine, 2021, 60, 001-008.	1.2	1
23	Improving sample size recalculation in adaptive clinical trials by resampling. Pharmaceutical Statistics, 2021, 20, 1035-1050.	1.3	0
24	Critical Illness and Systemic Inflammation Are Key Risk Factors of Severe Acute Kidney Injury in Patients With COVID-19. Kidney International Reports, 2021, 6, 905-915.	0.8	22
25	A new basket trial design based on clustering of homogeneous subpopulations. Journal of Biopharmaceutical Statistics, 2021, 31, 425-447.	0.8	5
26	Statistical model building: Background "knowledge"-based on inappropriate preselection causes misspecification. BMC Medical Research Methodology, 2021, 21, 196.	3.1	7
27	Efficacy of intraoperative specimen radiography as margin assessment tool in breast conserving surgery. Breast Cancer Research and Treatment, 2020, 179, 425-433.	2.5	16
28	Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint. BMC Medical Research Methodology, 2020, 20, 274.	3.1	3
29	Comprehensive survey among statistical members of medical ethics committees in Germany on their personal impression of completeness and correctness of biostatistical aspects of submitted study protocols. BMJ Open, 2020, 10, e032864.	1.9	1
30	Prediction of pathological complete response in breast cancer patients during neoadjuvant chemotherapy: Is shear wave elastography a useful tool in clinical routine?. European Journal of Radiology, 2020, 128, 109025.	2.6	14
31	Reevaluation of risk factors for time to subsequent events after first stroke occurrence using a new weighted all-cause effect measure. BMC Public Health, 2020, 20, 817.	2.9	2
32	Why do you need a biostatistician?. BMC Medical Research Methodology, 2020, 20, 23.	3.1	16
33	A new conditional performance score for the evaluation of adaptive group sequential designs with sample size recalculation. Statistics in Medicine, 2020, 39, 2067-2100.	1.6	7
34	Systematic review of education and practical guidance on regression modeling for medical researchers who lack a strong statistical background: Study protocol. PLoS ONE, 2020, 15, e0241427.	2.5	3
35	A variational approach to optimal two-stage designs. Statistics in Medicine, 2019, 38, 4159-4171.	1.6	16
36	Psychometric validation of the Breast Cancer Treatment Outcome Scale (BCTOS-12): a prospective cohort study. Archives of Gynecology and Obstetrics, 2019, 300, 1679-1686.	1.7	5

#	ARTICLE	IF	CITATIONS
37	Refining scores based on patient reported outcomes – statistical and medical perspectives. BMC Medical Research Methodology, 2019, 19, 167.	3.1	30
38	Introducing a new estimator and test for the weighted all-cause hazard ratio. BMC Medical Research Methodology, 2019, 19, 118.	3.1	2
39	What makes a biostatistician?. Statistics in Medicine, 2019, 38, 695-701.	1.6	14
40	Hepatitis E seroprevalence in the Americas: A systematic review and meta-analysis. Liver International, 2018, 38, 1951-1964.	3.9	44
41	Revival of transcatheter PFO closure: A meta-analysis of randomized controlled trials - impact of shunt size and age. American Heart Journal, 2018, 201, 95-102.	2.7	8
42	Time-to-first-event versus recurrent-event analysis: points to consider for selecting a meaningful analysis strategy in clinical trials with composite endpoints. Clinical Research in Cardiology, 2018, 107, 437-443.	3.3	17
43	A weighted combined effect measure for the analysis of a composite time-to-first-event endpoint with components of different clinical relevance. Statistics in Medicine, 2018, 37, 749-767.	1.6	21
44	Initial results of the FUSION-X-US prototype combining 3D automated breast ultrasound and digital breast tomosynthesis. European Radiology, 2018, 28, 2499-2506.	4.5	21
45	Development and psychometric validation of a shorter version of the Breast Cancer Treatment Outcome Scale (BCTOS-12). Breast, 2018, 38, 58-65.	2.2	12
46	Study on sacroiliac joint diagnostics. Manuelle Medizin, 2018, 56, 239-248.	0.1	3
47	RESPONDER – diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial. BMC Cancer, 2018, 18, 851.	2.6	32
48	Cardiac Implantable Electronic Device Interrogation at Forensic Autopsy. Circulation, 2018, 137, 2730-2740.	1.6	29
49	Blinded sample size recalculation in clinical trials with binary composite endpoints. Journal of Biopharmaceutical Statistics, 2017, 27, 705-715.	0.8	8
50	Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). European Journal of Cancer, 2017, 76, 60-67.	2.8	88
51	Reciprocal Interaction of 24-Hour Blood Pressure Variability and Systolic Blood Pressure on Outcome in Stroke Thrombolysis. Stroke, 2017, 48, 1827-1834.	2.0	30
52	Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network. Archives of Gynecology and Obstetrics, 2017, 295, 1239-1245.	1.7	42
53	In obesity even young women suffer from urogynecological symptoms. Archives of Gynecology and Obstetrics, 2017, 296, 947-956.	1.7	10
54	Inter-rater reliability and double reading analysis of an automated three-dimensional breast ultrasound system: comparison of two independent examiners. Archives of Gynecology and Obstetrics, 2017, 296, 571-582.	1.7	9

#	ARTICLE	IF	CITATIONS
55	Choice of futility boundaries for group sequential designs with two endpoints. BMC Medical Research Methodology, 2017, 17, 119.	3.1	19
56	Definition and Rationale. Springer Series in Pharmaceutical Statistics, 2017, , 3-7.	0.0	1
57	Descriptive Analysis of the Components. Springer Series in Pharmaceutical Statistics, 2017, , 191-204.	0.0	0
58	Clinical Trial Examples with (Composite) Time-to-Event Endpoints. Springer Series in Pharmaceutical Statistics, 2017, , 225-248.	0.0	0
59	Weighted Composite Time-to-Event Endpoint. Springer Series in Pharmaceutical Statistics, 2017, , 151-155.	0.0	0
60	Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03). Radiation Oncology, 2016, 11, 77.	2.7	22
61	Do Contralateral Prophylactic Mastectomies Help Patients?. Journal of Clinical Oncology, 2016, 34, 4191-4191.	1.6	1
62	LECANDUS study (LEsion CANDidate Detection in UltraSound Data): evaluation of image analysis algorithms for breast lesion detection in volume ultrasound data. Archives of Gynecology and Obstetrics, 2016, 294, 423-428.	1.7	5
63	Performance of e-ASPECTS software in comparison to that of stroke physicians on assessing CT scans of acute ischemic stroke patients. International Journal of Stroke, 2016, 11, 438-445.	5.9	129
64	Change of Patient-Reported Aesthetic Outcome Over Time and Identification of Factors Characterizing Poor Aesthetic Outcome After Breast-Conserving Therapy: Long-Term Results of a Prospective Cohort Study. Annals of Surgical Oncology, 2016, 23, 1744-1751.	1.5	33
65	A mother-child intervention program in adolescent mothers and their children to improve maternal sensitivity, child responsiveness and child development (the TeeMo study): study protocol for a randomized controlled trial. Trials, 2015, 16, 230.	1.6	14
66	Combination of Trabectedin and Gemcitabine for Advanced Soft Tissue Sarcomas: Results of a Phase I Dose Escalating Trial of the German Interdisciplinary Sarcoma Group (GISG). Marine Drugs, 2015, 13, 379-388.	4.6	9
67	Two-stage designs for cross-over bioequivalence trials. Statistics in Medicine, 2015, 34, 2403-2416.	1.6	24
68	Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. British Journal of Cancer, 2015, 113, 1565-1570.	6.4	83
69	Application of Cervical Collars "An Analysis of Practical Skills of Professional Emergency Medical Care Providers. PLoS ONE, 2015, 10, e0143409.	2.5	27
70	Opportunities and challenges of clinical trials in cardiology using composite primary endpoints. World Journal of Cardiology, 2015, 7, 1.	1.5	18
71	Combined sunitinib and IMRT for preoperative treatment of locally advanced soft tissue sarcoma: Results of a phase I trial of the German Interdisciplinary Sarcoma Group GISG 03.. Journal of Clinical Oncology, 2015, 33, 10541-10541.	1.6	0
72	Evaluation of Virtual Touch Tissue Imaging Quantification, a New Shear Wave Velocity Imaging Method, for Breast Lesion Assessment by Ultrasound. BioMed Research International, 2014, 2014, 1-7.	1.9	77

#	ARTICLE	IF	CITATIONS
73	Opportunities and challenges of combined effect measures based on prioritized outcomes. <i>Statistics in Medicine</i> , 2014, 33, 1104-1120.	1.6	44
74	Competing time-to-event endpoints in cardiology trials: A simulation study to illustrate the importance of an adequate statistical analysis. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 74-80.	1.8	18
75	Easily applicable multiple testing procedures to improve the interpretation of clinical trials with composite endpoints. <i>International Journal of Cardiology</i> , 2014, 175, 126-132.	1.7	9
76	Normal breast tissue stiffness measured by a new ultrasound technique: Virtual touch tissue imaging quantification (VTIQ). <i>European Journal of Radiology</i> , 2013, 82, e676-e679.	2.6	61
77	Multiplicity Adjustment for Composite Binary Endpoints. <i>Methods of Information in Medicine</i> , 2012, 51, 309-317.	1.2	16
78	A New Outlier Identification Test for Method Comparison Studies Based on Robust Regression. <i>Journal of Biopharmaceutical Statistics</i> , 2010, 21, 151-169.	0.8	5
79	Optimal unplanned design modification in adaptive two-stage trials. <i>Pharmaceutical Statistics</i> , 0, , .	1.3	0
80	Two-stage designs with small sample sizes. <i>Journal of Biopharmaceutical Statistics</i> , 0, , 1-7.	0.8	0